Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer

BACKGROUND: The neuroendocrine (NE) pathway cannot be ignored as a mechanism for castration‐resistant prostate cancer (CRPC) progression. The neuromediator, gastrin‐releasing peptide (GRP) may be involved in the aberrant activation of the normal androgen receptor (AR) and increased AR variants. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Yashi, Masahiro, Nishihara, Daisaku, Yokoyama, Megumi, Fuchizawa, Hirotaka, Okazaki, Akihito, Takei, Kohei, Suzuki, Issei, Sakamoto, Kazumasa, Kijima, Toshiki, Kobayashi, Minoru, Kamai, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026284/
https://www.ncbi.nlm.nih.gov/pubmed/36470854
http://dx.doi.org/10.1002/cnr2.1762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026284/
https://www.ncbi.nlm.nih.gov/pubmed/36470854
http://dx.doi.org/10.1002/cnr2.1762

Ejemplares similares